Team:HokkaidoU Japan/Safety

From 2011.igem.org

(Difference between revisions)
(→Safety proposal)
Line 2: Line 2:
==Safety proposal==
==Safety proposal==
-
1. Would any of your project ideas raise safety issues in terms of:
+
1. Would the materials used in your project and/or your final product pose:
-
* researcher safety,
+
* Risks to the safety and health of team members or others in the lab?
-
* public safety, or
+
* Risks to the safety and health of the general public if released by design or accident?
-
* environmental safety?
+
* Risks to environmental quality if released by design or accident?
 +
* Risks to security through malicious misuse by individuals, groups or states?
Our study will not contain any manipulation associated with pathogenic bacteria, live salmonella bacteria. Although we are planning to use a part of Salmonella's genome which was obtained from Salmonella Genetic Stock Centre (SGSC), our instructor obtained appropriate permission from the safety officer of genetic recombination (SOOGR) in our university. These E. coli were acknowledged as non-pathogenic and permitted to be used under P1 safety level.
Our study will not contain any manipulation associated with pathogenic bacteria, live salmonella bacteria. Although we are planning to use a part of Salmonella's genome which was obtained from Salmonella Genetic Stock Centre (SGSC), our instructor obtained appropriate permission from the safety officer of genetic recombination (SOOGR) in our university. These E. coli were acknowledged as non-pathogenic and permitted to be used under P1 safety level.
Line 19: Line 20:
* How could other teams learn from your experience?
* How could other teams learn from your experience?
-
Currently there are no BioBricks which raise any safety issues.
+
Currently there are no BioBricks which raise any safety issues. Some of our BioBricks are intended to use with Type 3 Secretion System. However we did not submit Type 3 Secretion System to BioBrick Registry. Parts of Salmonella's genome library should be directly obtained from Salmonella Genetic Stock Centre with appropriate permits.
Line 26: Line 27:
* If no, which specific biosafety rules or guidelines do you have to consider in your country?
* If no, which specific biosafety rules or guidelines do you have to consider in your country?
-
We have “the Safety Office of Genetic Recombination in Hokkaido University”.
+
We have “the Safety Office of Genetic Recombination in Hokkaido University”. Our lab was permitted to use E. coli containing following parts of salmonella genome library.
-
 
+
-
4. Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?
+
-
 
+
-
Currently we don't have any suggestions.
+
-
 
+
-
<!--
+
-
 
+
-
Further Questions
+
-
 
+
-
1. Would the materials used in your project and/or your final product pose:
+
-
* Risks to the safety and health of team members or others in the lab?
+
-
* Risks to the safety and health of the general public if released by design or accident?
+
-
* Risks to environmental quality if released by design or accident?
+
-
* Risks to security through malicious misuse by individuals, groups or states?
+
-
 
+
-
We are using following parts of salmonella genome library.
+
-
BAC clones of S. Typhimurium,
+
B_STM02P01　SGSC4014　837453-941863  
B_STM02P01　SGSC4014　837453-941863  
B_STM07H21  SGSC4024  1464540-1562427
B_STM07H21  SGSC4024  1464540-1562427
-
These were obtained from SGSC. SGSC4024 contains Salmonella Pathogenecity Island Two (SPI2) coding sequence which codes for Type Three Secretion System (T3SS) used after Salmonella invades cell. For salmonella to be pathogenic T3SS coded on Salmonella Pathogenecity Island One (SPI1) is required. So there is no threat of the E.coli with this BAC vector to be pathogenic. SGSC4014 doesn't code neither SPI1 nor SPI2 so it also doesn't rise safety concerns.
+
4. Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?
-
 
+
-
2.  If your response to any of the questions above is yes:
+
-
* Explain how you addressed these issues in project design and while conducting laboratory work.
+
-
* Describe and document safety, security, health and/or environmental issues as you submit your parts to the Registry.
+
 +
For our injection essay we planed to use GSK tag ,which is documented on our wiki, for identifying proteins injected into eucaryotic cells by type 3 secretion system.
-
3. Under what biosafety provisions will / do you operate?
+
The system for screening proteins submited to BioBrick Registry can be put in place. This system can detect proteins which can enter eucaryotic cells. This can be used to asses potential for safety isues.
-
* Does your institution have its own biosafety rules and if so what are they?  Provide a link to them online if possible.
+
-
* Does your institution have an Institutional Biosafety Committee or equivalent group? If yes, have you discussed your project with them? Describe any concerns or changes that were made based on this review.
+
-
* Will / did you receive any biosafety and/or lab training before beginning your project? If so, describe this training.
+
-
* Does your country have national biosafety regulations or guidelines?  If so, provide a link to them online if possible.
+
-
-->
 
{{Team:HokkaidoU_Japan/footer}}
{{Team:HokkaidoU_Japan/footer}}

Revision as of 02:37, 6 October 2011

Contents

Safety proposal

1. Would the materials used in your project and/or your final product pose:

  • Risks to the safety and health of team members or others in the lab?
  • Risks to the safety and health of the general public if released by design or accident?
  • Risks to environmental quality if released by design or accident?
  • Risks to security through malicious misuse by individuals, groups or states?

Our study will not contain any manipulation associated with pathogenic bacteria, live salmonella bacteria. Although we are planning to use a part of Salmonella's genome which was obtained from Salmonella Genetic Stock Centre (SGSC), our instructor obtained appropriate permission from the safety officer of genetic recombination (SOOGR) in our university. These E. coli were acknowledged as non-pathogenic and permitted to be used under P1 safety level.

Permit for using particular parts of Salmonella's genome library was obtained on the basis that genetic information encoded in them is not sufficient to express pathogenicity in E. coli.

Our lab is equipped appropriately for the manipulation and genetic recombination of bacterial cells. Team members are instructed according to the safety training manual.


2. Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes,

  • did you document these issues in the Registry?
  • how did you manage to handle the safety issue?
  • How could other teams learn from your experience?

Currently there are no BioBricks which raise any safety issues. Some of our BioBricks are intended to use with Type 3 Secretion System. However we did not submit Type 3 Secretion System to BioBrick Registry. Parts of Salmonella's genome library should be directly obtained from Salmonella Genetic Stock Centre with appropriate permits.


3. Is there a local biosafety group, committee, or review board at your institution?

  • If yes, what does your local biosafety group think about your project?
  • If no, which specific biosafety rules or guidelines do you have to consider in your country?

We have “the Safety Office of Genetic Recombination in Hokkaido University”. Our lab was permitted to use E. coli containing following parts of salmonella genome library.

B_STM02P01　SGSC4014　837453-941863 B_STM07H21 SGSC4024 1464540-1562427

4. Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?

For our injection essay we planed to use GSK tag ,which is documented on our wiki, for identifying proteins injected into eucaryotic cells by type 3 secretion system.

The system for screening proteins submited to BioBrick Registry can be put in place. This system can detect proteins which can enter eucaryotic cells. This can be used to asses potential for safety isues.


Retrieved from "http://2011.igem.org/Team:HokkaidoU_Japan/Safety"